Creative Medical Technology Holdings Inc. - Prakiraan wutah bathi kanggo taun ngarep CELZ

Creative Medical Technology (CELZ) relies on regenerative technologies, where R&D expenditures render cash flows unstable. The next-year EPS growth forecasting model on the GURU.Markets daily chart reflects that the parameter value is 30.40. The business is independent of market cycles, as drug discovery is a lengthy process and current profit catalysts are expected only in the long term.

This indicator reflects the aggregate expert forecast regarding net profit growth rates, allowing investors to assess the fundamental growth potential of the business for the coming year. When analyzing the history of consensus earnings growth estimates for the following year on the GURU.Markets platform, it should be noted that for Creative Medical Technology (CELZ), the commercial impact of cell immunotherapy is delayed due to lengthy clinical trials, which the market has already priced into the current valuation.